Cogent Biosciences Inc. has announced multiple upcoming poster presentations featuring results from the SUMMIT trial evaluating bezuclastinib in adults with nonadvanced systemic mastocytosis (NonAdvSM) at the 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, scheduled for February 27–March 2, 2026, in Philadelphia, PA. The company recently submitted a New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration, based on positive clinical data from the pivotal SUMMIT trial. The presentations will cover expanded clinical results, exploratory analyses of bone formation markers, outcomes in patient subgroups with unmet needs, patient experiences, and correlations between symptom improvement and objective disease measures. The results will be presented at the conference and have not yet been publicly disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651659) on February 10, 2026, and is solely responsible for the information contained therein.